Skip to main content
Premium Trial:

Request an Annual Quote

Athersys Files Patents For 10,000-Plus Genes, Collaborates with Acorda

Premium

C

LEVELAND--Athersys, a genomics company based here, has filed US patent applications covering more than 10,000 novel gene sequences identified using the company’s Random Activation of Gene Expression for Gene Discovery technology. The company believes that many of these genes encode novel G-coupled protein receptors, secreted proteins, ion channels, protein kinases, proteases, and other potential drug targets and therapeutic candidates, based on bioinformatics and expression analysis. The RAGE-GD technology enables the activation and expression of any gene in the human genome, including those that are ordinarily silent in most tissues, without requiring the cloning of cDNA or genomic DNA sequences that encode specific genes, said Athersys.

In other news, Athersys has formed a functional genomics collaboration with Acorda Therapeutics of New York, to discover validated drug targets to treat certain central nervous system disorders, including spinal cord injuries and multiple sclerosis.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.